URGN (UroGen) Gross Profit Margin

URGN (UroGen Pharma Ltd) - company brandmark

International shipments of UroGen Pharma Ltd. (URGN) products are carried out through verified operators, ensuring supply chain stability. The gross margin history is derived from GURU.Markets chart data, where the value 91.40 captures this performance metric. The company's revenues are based on the sale of patented therapies for kidney and bladder cancer. The business potential relies on the development of innovative RTGel hydrogels for local urothelium treatment.

URGN - urogen.com Return on Gross Profit over the range 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for UroGen Pharma Ltd. (URGN)

- market price and analyst price targets:
- business market valuation indicators:
Fundamental valuation:UroGen Pharma Ltd.
Product sample of UroGen Pharma Corp

Gross margin measures production efficiency by determining the portion of revenue remaining after deducting direct product costs, allowing for an assessment of the fundamental profitability of each unit. By analyzing historical gross margins, an investor can evaluate the profitability of UroGen Pharma Ltd. (URGN) gel formulations, which is critical for assessing the monetization of Jelmyto and controlling operating expenses during the market launch of UGN-102.

Main competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|Bicara Therapeutics - Return on Gross Profit|Gross Margin Personalis Inc PSNL|Erasca Oncology - Gross Margin|Gross Profit Rate DCTH (Delcath Corp)|YMAB: Gross Margin|AURA - Return on Sales by Gross Profit|CADL (Candel Therapeutics Inc.) - Gross Margin|Gross Return on Sales ARAY (Accuray)|Return on Gross Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Gross Profit Margin|Gross Profitability Citius Oncology, Inc. CTOR|HURA - Return on Gross Profit|protaratx.com - Gross Margin|FATE - Gross Margin|WHWK: Gross Margin|TScan Therapeutics (TCRX) - Gross Margin|Gross Profitability Champions Oncology|Gross Profitability XBIT|Gross Margin CVM|Return on Gross Profit OS Therapies Inc. OSTX|Gross Profitability Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Gross Profit Margin|ANL - Gross Profitability|Gross Profit Margin verupharma.com|TPST: Gross Margin|XLO - Return on Sales by Gross Profit|Gross Profitability Renovaro|Gross Margin muraloncology.com|Gross Margin KAPA|Return on Sales by Gross Profit OnKure Therapeutics, Inc.|Gross Margin GDTC (w2.cytomed.sg)|CRIS - Return on Gross Profit|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit